The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1118-1125, November 2007

Computed tomographic scan–diagnosed chronic obstructive pulmonary disease–emphysema: Eotaxin-1 is associated with bronchodilator response and extent of emphysema

  • Marina Miller, MD, PhD

      Affiliations

    • Department of Medicine, University of California, San Diego, La Jolla, Calif
  • ,
  • Joe Ramsdell, MD

      Affiliations

    • Department of Medicine, University of California, San Diego, La Jolla, Calif
  • ,
  • Paul J. Friedman, MD

      Affiliations

    • Department of Radiology, University of California, San Diego, La Jolla, Calif
  • ,
  • Jae Youn Cho, MD, PhD

      Affiliations

    • Department of Medicine, University of California, San Diego, La Jolla, Calif
  • ,
  • Marian Renvall, MS

      Affiliations

    • Department of Medicine, University of California, San Diego, La Jolla, Calif
  • ,
  • David H. Broide, MB, ChB

      Affiliations

    • Department of Medicine, University of California, San Diego, La Jolla, Calif
    • Corresponding Author InformationReprint requests: David H. Broide, MB, ChB, University of California, San Diego, Biomedical Sciences Building, Room 5090, 9500 Gilman Dr, La Jolla, CA 92093-0635.

Received 20 October 2006; received in revised form 27 July 2007; accepted 6 August 2007.

Background

Bronchodilator responses are a hallmark of asthma and a subset of chronic obstructive pulmonary disease (COPD). We evaluated subjects with COPD and computed tomographic (CT) scan evidence of emphysema to determine the biomarker profile associated with a bronchodilator response.

Objective

We investigated whether subjects with COPD and a bronchodilator response had increased levels of bronchoalveolar lavage (BAL) fluid eosinophil biomarkers, TH2 cytokines, CC chemokines, and serum allergen-specific IgE.

Methods

All patients with COPD and control subjects (n = 31) had chest CT scans to detect emphysema and subsequent pulmonary function studies, BAL for biomarkers, and serum IgE measurements.

Results

CT scan score, FEV1, carbon monoxide single-breath diffusion capacity, and BAL fluid neutrophil biomarker levels were similar in subjects with COPD who had or did not have a bronchodilator response of greater than 12%. In contrast, levels of BAL fluid eosinophil biomarkers (eosinophil cationic protein [ECP] and eotaxin-1) were greater in patients with COPD with a bronchodilator response, whereas TH2 cytokines were not detectable in any patients with COPD. BAL fluid ECP and eotaxin-1 levels correlated with CT scan extent of emphysema. Immunostaining of COPD lung sections from a separate cohort of subjects with COPD and healthy subjects demonstrated epithelial expression of eotaxin-1 but no lung expression of IL-4 or IL-5.

Conclusion

Subjects with COPD diagnosed on the basis of the presence of emphysema on CT scan who have a bronchodilator response have increased levels of BAL ECP and eotaxin-1 but not TH2 cytokines.

Clinical implications

Eosinophil biomarkers (ECP-1 and eotaxin-1) might identify a subset of subjects with COPD with emphysema on CT scans who have a bronchodilator response and an increased extent of emphysema on CT scanning.

Key words: Asthma, eosinophil, eotaxin, cytokines, chemokines

Abbreviations used: BAL, Bronchoalveolar lavage, COPD, Chronic obstructive pulmonary disease, COPD-E, Chronic obstructive pulmonary disease–emphysema, COPD-E (BD+), Chronic obstructive pulmonary disease–emphysema with bronchodilator response, COPD-E (BD−), Chronic obstructive pulmonary disease–emphysema with no bronchodilator response, CT, Computed tomography, Dlco, Carbon monoxide single-breath diffusion capacity, ECP, Eosinophil cationic protein, GOLD, Global Initiative for Chronic Obstructive Lung Disease, LTB4, Leukotriene B4, MPO, Myeloperoxidase, UCSD, University of California San Diego

 

 Supported by National Institutes of Health grants HL72342 and GCRC MO1RR000827.

 Disclosure of potential conflict of interest: M. Miller, J. Ramsdell, P. J. Friedman, J. Y. Cho, M. Renvall, and D. H. Broide have received grant support from the National Institutes of Health.

PII: S0091-6749(07)01644-2

doi:10.1016/j.jaci.2007.08.045

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1118-1125, November 2007